<DOC>
	<DOCNO>NCT02024581</DOCNO>
	<brief_summary>This trial examine safety , tolerability efficacy one strength East Indian sandalwood oil ( EISO ) cream base compare placebo treatment molluscum contagiosum pediatric subject . Trial participant ask apply study medication twice day sixty ( 60 ) day . Efficacy evaluate clinical staff patient ask assess tolerability well improvement experience trial .</brief_summary>
	<brief_title>A Dose Range-Finding Phase 2 Trial Botanical Drug Treatment Molluscum Contagiosum Pediatric Subjects</brief_title>
	<detailed_description>This trial single-center , double-blind , randomize , placebo-controlled safety efficacy trial evaluate efficacy safety VIR003 treatment regimen administer pediatric subject molluscum contagiosum . Once subject eligibility confirm subject start Treatment Period study . All subject receive active treatment placebo first dose apply Day 0 Study Visit . Subjects instruct apply study medication twice day 90 day treatment . Subjects return clinic Study Days , 7 , 14 , 30 , 45 , 60 90 routine evaluation Study Day 97 Final Study Visit . Safety assess evaluate adverse event ( AEs ) respect severity , duration , relationship study drug . In addition tolerability evaluation perform study visit . The preliminary efficacy evaluation study resolution molluscum contagiosum lesion Study Day 90 evaluable subject .</detailed_description>
	<mesh_term>Molluscum Contagiosum</mesh_term>
	<criteria>Subjects include trial meet follow criterion : Are 2 17 year age , inclusive , screen . Have diagnosis molluscum contagiosum treatable topical agent least five ( 5 ) lesion treatment area . Are free systemic dermatologic disorder , , opinion investigator interfere study result increase risk adverse event . Are willing refrain use nonapproved lotion , sunscreen , moisturizer , cleanser , cosmetic cream affected area treatment period . Whose parent guardian able give write informed consent potential pediatric subject 7 year age old provide assent manner approve Institutional Review Board comply requirement study . Subjects exclude trial meet follow criterion : Are immunosuppressed . Have regular physical contact sibling person molluscum contagiosum virus ( MCV ) , unless person also enrol study . Have use planning use immunosuppressive immunomodulatory medication ( include oral parenteral corticosteroid ) previous 30 day . Are undergoing treatment treat last 30 day prior Screening isotretinoin type topical therapy ( e.g. , corticosteroid , cantharidin , podophyllin , podofilox , iodine , salicylic acid , retinoids , diclofenac , hyaluronic acid , potassium hydroxide , imiquimod ) . Have use liquid nitrogen treatment area last 30 day prior Screening . Have undergone curettage , electrocoagulation , tap clamp infected area . Are take antiviral medication include limited cimetidine cidofovir . Have active skin malignancy infection molluscum contagiosum . Have molluscum contagiosum infection untreatable area ( i.e. , mucosal surface , anogenital , periorbital , facial region ) . Have condition opinion investigator would confound safety and/or efficacy assessment . Have participate clinical trial previous 30 day . Have know sensitivity constituent test product include sensitivity sandalwood oil , fragrances member Compositae family vascular plant ( e.g. , sunflower , daisy , dahlia , etc. ) . Are pregnant , breastfeeding , unwilling practice acceptable form birth control study , applicable . Have present condition abnormality opinion Investigator would compromise safety subject quality data .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>pediatric</keyword>
	<keyword>dermatology</keyword>
	<keyword>East Indian sandalwood oil</keyword>
	<keyword>pox virus</keyword>
</DOC>